Dried Blood Spots Combined With Ultra-High-Performance Liquid Chromatography-Mass Spectrometry for the Quantification of the Antipsychotics Risperidone, Aripiprazole, Pipamperone, and Their Major Metabolites
Tron et al.
The finding, in our words
A UHPLC-MS/MS assay for risperidone, aripiprazole, pipamperone and their metabolites in dried blood spots was validated for therapeutic drug monitoring. The method proved accurate across haematocrit values of 30-45 percent, remained stable for ten days at room temperature, and was successfully applied to patient samples, enabling decentralised monitoring in children with autism spectrum disorders.
A paraphrase to the Library’s standard, never the abstract. The source is one link away and is always the authority.
A review of dried blood microsampling for tyrosine kinase inhibitor monitoring, covering the analytical and clinical requirements for moving oral cancer-drug TDM out of hospital.
Verougstraete et al., Frontiers in Oncology · source ↗
Dried blood spot microsampling provides a patient-centric alternative to venous sampling for therapeutic drug monitoring, with advantages of home self-collection, small sample volumes suitable for children, and analyte stability, though accuracy is affected by haematocrit and requires patient correlation studies to validate clinical equivalence.
Wilhelm et al., Clinical pharmacokinetics · source ↗
In AML and CLL, 91% of VAMS venetoclax results fell within 20% of plasma after individualised haematocrit correction; in home sampling, 18 of 21 patients self-sampled independently and 76% of returned samples were analysable, which shows home microsampling is workable, though the authors ask for multicentre validation.
Levens et al., Clinical Pharmacokinetics (paywalled) · source ↗
This review found that volumetric microsampling devices, such as Mitra, HemaPEN, HemaXis DB10, and Tasso-M20, overcome haematocrit bias, whilst Telimmune plasma separation cards enable direct plasma collection without centrifugation. These technologies support patient-centric, decentralised sampling, though the authors note that clinical validation remains limited across different drugs and patient populations.
Huhn & Scherf-Clavel, Therapeutic drug monitoring (paywalled) · source ↗
A systematic review found mixed economic evidence for microsampling in therapeutic drug monitoring; one study reported no cost reduction with DBS home-sampling, €688 versus €676, whilst another predicted savings up to 61%. The authors caution that more work is required to assess costs alongside clinical outcomes and optimise logistics for decentralised implementation.
Carland et al., British Journal of Clinical Pharmacology (paywalled) · source ↗